Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market

AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.

Lung model

Details of Phase III trials for AstraZeneca PLC’s first biologic respiratory medicine benralizumab released at the European Respiratory Society International Congress on Sept. 5 show the monoclonal antibody directly and quickly killed inflammatory cells called eosinophils which drive inflammation and airway hyper-responsiveness in around 50% of asthma patients.

In an interview with Scrip, Tom Keith-Roach, who leads AstraZeneca’s respiratory, inflammation and autoimmune business, was optimistic about the product's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category